Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
05/2003
05/27/2003CA2387361C Crystal form 0 and form ii of clarithromycin and uses thereof
05/27/2003CA2387356C Crystal form 0 and form i of clarithromycin and uses thereof
05/27/2003CA2386527C Crystal form i of clarithromycin
05/27/2003CA2277274C Crystal form 0 of clarithromycin
05/27/2003CA2258606C Crystal form ii of clarithromycin
05/27/2003CA2231558C .gamma.-rar antagonist ligand or .alpha.-rar agonist ligand as an apoptosis inhibitor
05/27/2003CA2199747C 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof
05/27/2003CA2176229C Improved interferon polymer conjugates
05/27/2003CA2158455C Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
05/22/2003WO2003042388A1 Polypeptide antigen forming a mimetic structure of the gp41 intermediate state
05/22/2003WO2003042377A1 Expansion of t cells in vitro and expanded t cell populations
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042240A2 Polypeptides of pseudomonas aeruginosa
05/22/2003WO2003042228A1 Macrolides
05/22/2003WO2003042219A1 Novel c-3 s/o- and s/n formaldehe acetal derivatives of cephalo sporins and their use as antibiotics
05/22/2003WO2003042205A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042191A1 Benzamide and heteroarylamide as p2x7 receptor antagonists
05/22/2003WO2003042190A1 N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
05/22/2003WO2003042188A1 Triazole derivative and medicinal composition containing the same
05/22/2003WO2003042186A1 Dithiocarbamate derivatives and their use as antibacterial agents
05/22/2003WO2003042177A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003041754A1 Medical devices having antimicrobial coatings thereon
05/22/2003WO2003041734A1 Salmonella vaccine
05/22/2003WO2003041723A1 Pharmaceutical applications of hyaluronic acid preparations
05/22/2003WO2003041721A1 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments
05/22/2003WO2003041710A1 Methods for preventing or treating disease mediateb by toxin-secreting bacteria
05/22/2003WO2003041702A1 Production of pure stereoisomers of tricyclo[5.2.1.02.6]-dec-9-yl xanthogenate and medicaments therefrom
05/22/2003WO2003041694A2 Use of compounds comprising iodine, strontium and ascorbic acid as well as either bismuth, zinc or potassium in the treatment of aids
05/22/2003WO2003041689A1 Biocompatible polymer blends and uses thereof
05/22/2003WO2003041686A2 Improved therapy for topical diseases
05/22/2003WO2003041660A2 Solubilized topoisomerase poisons
05/22/2003WO2003041647A2 Synthesis and purification of valacyclovir
05/22/2003WO2003027255A3 Anti-fusion assay
05/22/2003WO2003020763A3 Soluble t cell receptor
05/22/2003WO2003020732A3 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors.
05/22/2003WO2003011277A3 Methods to mobilize progenitor/stem cells
05/22/2003WO2003007883A3 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
05/22/2003WO2002102836A3 Moraxella (branhamella) catarrhalis antigens
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002085886A3 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
05/22/2003WO2002083120A3 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
05/22/2003WO2002078709A3 Use of pyrido`2,3-d pyrimidin derivatives for the treatment of human cytomegalovirus infections
05/22/2003WO2002076403A3 Methods for the treatment of hiv and other viruses
05/22/2003WO2002072754A3 Mva expressing modified hiv envelope, gag, and pol genes
05/22/2003WO2002058737A3 Multivalent meningococcal polysaccharide-protein conjugate vaccine
05/22/2003WO2002051430A3 Methods of modulating toll-related receptor (trr) signaling
05/22/2003WO2002045749A8 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
05/22/2003WO2002044183A3 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
05/22/2003WO2002044168A3 Indole-type inhibitors of p38 kinase
05/22/2003WO2002041891A3 Hiv treatment with benzimidazoles
05/22/2003WO2001070941A9 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
05/22/2003US20030097004 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
05/22/2003US20030096998 As immunomodulators and for inducing cytokine biosynthesis in animals, for therapy of viral infections
05/22/2003US20030096992 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
05/22/2003US20030096950 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
05/22/2003US20030096948 Acylating a destryptophan compound to obtain an ornithin amino protected compound, removing the ornithine protecting group; antibiotic daptomycin stereoisomeric compounds
05/22/2003US20030096874 For prophylaxis and therapy of respiratory diseases asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease
05/22/2003US20030096862 Stable NO-delivering compounds
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096850 Treating infections by administration of oxazolidinones
05/22/2003US20030096844 Cannabinoid receptor ligands
05/22/2003US20030096840 Granule formulation
05/22/2003US20030096838 Novel triazolo-pyridines anti-inflammatory compounds
05/22/2003US20030096835 Amido ether substituted imidazoquinolines
05/22/2003US20030096834 Pharmaceutical compositions
05/22/2003US20030096829 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096826 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family
05/22/2003US20030096825 Antiviral activity; treatment of HIV and AIDS
05/22/2003US20030096819 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
05/22/2003US20030096817 Inhibiting mammalian protein kinases (p38) with (2,6-difluoro-phenyl)-(5-iodo-pyridin-2-yl)amine for treatment of cardiovascular disorders
05/22/2003US20030096816 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
05/22/2003US20030096812 Such as 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid for treatment of systemic or topical infections
05/22/2003US20030096795 Calcium (3S) tetrahydro-3-furanyl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phos-phonooxy)propylcarbamate
05/22/2003US20030096787 Comprising the ITR sequences, a sequence permitting the encapsulation, a heterologous DNA sequence, and in which the E1 gene and at least one of the E2, E4 and L1-L5 genes is non-functional
05/22/2003US20030096774 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
05/22/2003US20030096765 Aromatic esters; cytotoxic agents; antitumor agents
05/22/2003US20030096763 4' -substituted leucomycins
05/22/2003US20030096758 Anticarcinogenic agents
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096745 A conjugated cecropins and magainins with one or more replaced peptides; bactericides, fungicides and anticarcinogenic agent; nontoxic
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096737 Caspase inhibitors and uses thereof
05/22/2003US20030096387 Contacting the isomerase with a compound having the structure: A-X-A, where A is radical which mimics the steric and electronic properties of phosphoserin and/or phosphothreonine residue, X= spacer, R is cyclic, heterocylic or aryl ring
05/22/2003US20030096370 Gram negative bacterial protein for use in the prevention and treatment of bacterial infection
05/22/2003US20030096368 Nucleotide sequences coding bactericide for use in the treatment and prevention of neisseria infections
05/22/2003US20030096352 Nucleotide sequences coding polypeptides for use in the treatment and prevention of viral and bacterial disease
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096338 Protein conjugate for use in the treatment of blood disorder
05/22/2003US20030096299 Natural ligand of G protein coupled receptor ChemR23 and uses thereof
05/22/2003US20030096297 Method for identifying inhibitors of G protein coupled receptor signaling
05/22/2003US20030096267 Essential bacterial genes and their use
05/22/2003US20030096250 Nucleotide sequences coding polypeptide for use in the prevention of bacterial infection of mammals
05/22/2003US20030095997 Preferably collagen; capable of promoting formation of granulation tissue, angiogenesis, vascularization and epithelization; useful in surgical suturing.
05/22/2003US20030095995 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
05/22/2003US20030095992 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots
05/22/2003US20030095987 Recombinant parainfluenza virus expression system and vaccines
05/22/2003US20030095984 Vaccine against mumps containing a Jeryl-Lynn virus strain
05/22/2003US20030095979 Xn-PeptideL-Xm, where X is Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp, Cys, Met, Glu or Asp; and PeptideL is a potentially immunogenic fragment; and a polycationic material; vaccines
05/22/2003US20030095973 Chlamydia antigens and corresponding DNA fragments and uses thereof
1 ... 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 ... 1798